Detailed Information on Publication Record
2017
F-18-FDG PET/CT in polymyalgia rheumatica-a pictorial review
ŘEHÁK, Zdeněk, Andrea ŠPRLÁKOVÁ-PUKOVÁ, Tomáš KAZDA, Zdeněk FOJTÍK, Lenka VARGOVÁ et. al.Basic information
Original name
F-18-FDG PET/CT in polymyalgia rheumatica-a pictorial review
Authors
ŘEHÁK, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Andrea ŠPRLÁKOVÁ-PUKOVÁ (203 Czech Republic), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Zdeněk FOJTÍK (203 Czech Republic, belonging to the institution), Lenka VARGOVÁ (203 Czech Republic, belonging to the institution) and Petr NĚMEC (203 Czech Republic, belonging to the institution)
Edition
BRITISH JOURNAL OF RADIOLOGY, LONDON, BRITISH INST RADIOLOGY, 2017, 0007-1285
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30224 Radiology, nuclear medicine and medical imaging
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.814
RIV identification code
RIV/00216224:14110/17:00098713
Organization unit
Faculty of Medicine
UT WoS
000411905200011
Keywords in English
Polymyalgia rheumatica
Tags
Tags
International impact, Reviewed
Změněno: 18/3/2018 23:06, Soňa Böhmová
Abstract
V originále
Polymyalgia rheumatica (PMR) is one of the inflammatory rheumatic diseases that can potentially be detected by positron emission tomography/CT. High fluorine-18 fludeoxyglucose (F-18-FDG) accumulation around the shoulders, sternoclavicular and hip joints are the most common pre-treatment features of patients with PMR. Another common sign is increased F-18-FDG uptake in extra-articular regions between columnal spinous processes, near ischial tuberosities and in the praepubic area. Some patients also present with high F-18-FDG uptake in main arteries, corresponding to the characteristics of giant cell arteritis. It is possible to observe a decrease or even a disappearance of F-18-FDG uptake after effective therapy, an event which may be useful for the monitoring of treatment as well as for detection of PMR relapse.